A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 145-152

  Chengappa, K N Roy ^a   Turkin, Scott R ^b   DeSanti, Susan ^c   Bowie, Christopher R ^d   Brar, Jaspreet S ^a   Schlicht, Patricia J ^a   Murphy, Sherry L ^b   Hetrick, Michelle L ^b   Bilder, Robert ^e   Fleet, David ^f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DuBois Regional Medical Center   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Datamagik   (United Kingdom)

Author keywords

Cognition; L carnosine; Perseverative errors; Randomized clinical trial; Schizophrenia; Set shifting

Indexed keywords

CARNOSINE; PLACEBO;

ADJUVANT THERAPY; ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTICLE; ATTENTION; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FEMALE; FOOT PAIN; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR PERFORMANCE; MULTICENTER STUDY; PARESTHESIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PNEUMONIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGIC TEST; QUALITY OF LIFE INTERVIEW; RANDOMIZED CONTROLLED TRIAL; RASH; RESPONSE TIME; SCHIZOPHRENIA; SHORT FORM 36; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; VIVID DREAM; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; ATTENTION; CARNOSINE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SIGNAL DETECTION, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84869879025     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.001     Document Type: Article

References (67)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC.
3. Arai M., Yuzawa H., Nohara I., Ohnishi T., Obata N., Iwayama Y., et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch. Gen. Psychiatry 2010, 67:589-597.
4. Bakardjiev A. Carnosine and β-alanine release is stimulated by glutamatergic receptors in cultured rat oligodendrocytes. Glia 1998, 24:346-351.
5. Barua P., Bilder R., Small A., Sharma T. Standardization and cross-validation study of cogtest an automated Neurocognitive battery for use in clinical trials of schizophrenia. Schizophr. Bull. 2001, 31:318.
6. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 2008, 64:61-368.
7. Boldyrev A.A., Stvolinsky S.L., Tyulina O.V., Koshelev V.B., Hori N., Carpenter D.O. Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals. Cell. Mol. Neurobiol. 1997, 17:259-271.
8. Bowie C.R., Twamley E.W., Anderson H., Halpern B., Patterson T.L., Harvey P.D. Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 2007, 41:1012-1018.
9. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63:505-511.
10. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164:1593-1602.
11. Ceaser A.E., Goldberg T.E., Egan M.F., McMahon R.P., Weinberger D.R., Gold J.M. Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype?. Biol. Psychiatry 2008, 64:782-788.
12. Chen H.-H., Stoker A., Markou A. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology 2010, 209:343-350.
13. Chez M.G., Buchanan C.P., Aimonovitch M.C., Becker M., Schaefer K., Black C., et al. Double-blind, placebo-controlled study of l-carnosine supplementation in children with autistic spectrum disorders. J. Child Neurol. 2002, 17:833-837.
14. Cohen J. Eta squared and partial eta-squared in fixed factor ANOVA designs. Educ. Psychol. Meas. 1973, 33:107-112.
15. Coman H., Nemes B., Nica S., Rusu I., Herta D., Cosman D. Reaction time and implicit learning in multiple episode schizophrenia patients. J. Cogn. Behav. Psychother. 2010, 10:147-160.
16. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689-695.
17. Devlin T. Textbook of Biochemistry with Clinical Correlations 2001, 1072-1073. Wiley Liss, New York. Fourth edition.
18. Dobrota D., Fedorova T., Stvolinsky S., Babusikova E., Likavcanova K., Drgova A., et al. Carnosine protects the brain of rats and Mongolian gerbils against ischemic injury: after-stroke-effect. Neurochem. Res. 2005, 30:1283-1288.
19. Gardner M.L. Intestinal absorption of the intact peptide carnosine in man, and comparison with intestinal permeability to lactulose. J. Physiol. 1991, 439:411-422.
20. Gjessing L.R., Lunde H.A., Morkrid L., Lenney J.F., Sjaastad O. Inborn errors of carnosine and homocarnosine metabolism. J. Neural Transm. 1990, 29:91-106.
21. Goldberg T.E., Weinberger D.R., Berman K.F., Pliskin N.H., Podd M.H. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch. Gen. Psychiatry 1987, 44:1008-1014.
22. Goto K., Maemura H., Takamatsu K., Ishii N. Hormonal responses to resistance exercise after ingestion of carnosine and anserine. J. Strength Cond. Res. 2011, 25:398-405.
23. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
24. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am. J. Psychiatry 2008, 165:221-228.
25. Harding J., Margolis F.L. Denervation in primary olfactory pathway of mice. 3. Effect of enzymes of carnosine metabolism. Brain Res. 1976, 110:351-360.
26. Hipkiss A.R., Preston J.E., Himsworth D.T.M., Worthington V.C., Abbott N.J. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endotheial cells. Neurosci. Lett. 1997, 238:135-138.
27. Hipkiss A.R., Preston J.E., Himsworth D.T., Worthington V.C., Keown M., Michaelis J., et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann. N. Y. Acad. Sci. 1998, 854:37-53.
28. Hutton S.B., Puri B.K., Duncan L.J., Robbins T.W., Barnes T.R., Joyce E.M. Executive function in first-episode schizophrenia. Psychol. Med. 1998, 28:463-473.
29. Jackson M.C., Lenney J.F. The distribution of carnosine and related dipeptides in rat and human tissues. Inflamm. Res. 1996, 45:32-135.
30. Javitt D.C. Glutamate involvement in schizophrenia: focus on N-methyl-d-aspartate receptors. Prim. Psychiatry 2006, 13:38-46.
31. Jin C.L., Yang L.X., Wu X.H., Li Q., Ding M.P., Fan Y.Y., et al. Effects of carnosine on amygdaloid-kindled seizures in Sprague-Dawley rats. Neuroscience 2005, 135:930-947.
32. Joyce E.M., Hutton S.B., Duncan L.J., Chapman M.J., Puri B.K., Robbins T.W., et al. Executive function in first episode schizophrenia: improvement at one year. Schizophr. Res. 1998, 29:53.
33. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
34. Keefe R.S.E. Cognitive deficits in patients with schizophrenia: effects and treatment. J. Clin. Psychiatry 2007, 68:8-13.
35. Kraepelin E. Psychiatrie: Ein Lehrbuch fur Studirende und Aetze. Funfte, vollstanding umgearbeitete Auflage. Barth, Leipzig, 1896. Die Erscheinungsformen des Irreseins. Z. Gesamte Neurol. Psychiatr. 1919, 62:1-29.
36. Krystal J.H., Bennett A., Abi-Saab D., Belger A., Karper L.P., D'Souza D.C., et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol. Psychiatry 2000, 47:137-143.
37. Kyriazis M. Carnosine and Other Elixirs of Youth 2003, Watkins Publishing, London.
38. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
39. Lehman A.F. A quality-of-life interview for the chronically mentally ill. Eval. Program Plann. 1988, 11:51-62.
40. Lenney J.F., George R.P., Weiss A.M., Kucera C.M., Chan P.W.H., Rhizler G.S. Human serum carnosinase: characterization, distinction from cellular carnosinase and activation by cadmium. Clin. Chim. Acta 1982, 123:221-231.
41. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43:674-679.
42. Maynard L.M., Boissonneault G.A., Chow C.K., Bruckner G.G. High levels of dietary carnosine are associated with increased concentrations of carnosine and histidine in rat soleus muscle. J. Nutr. 2001, 131:287-290.
43. McGurk S.R., Mueser K.T., Harvey P.D., LaPuglia R., Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr. Serv. 2003, 54:1129-1135.
44. Min J., Senue M.C., Rajanikant K., Greenberg E., Bandagi R., Zemke D., et al. Differential neuroprotective effects of carnosine, anserine, and N-acetyl- carnosine against permanent focal ischemia. J. Neurosci. Res. 2008, 86:2984-2991.
45. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
46. Pantelis C., Barber F.Z., Barnes T.R., Nelson H.E., Owen A.M., Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr. Res. 1999, 37:251-270.
47. Panzanelli P., Cantino D., Sassoe-Pognetto M. Co-localization of carnosine and glutamate in photoreceptors and bipolar cells of the frog retina. Brain Res. 1997, 758:143-152.
48. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27:235-245.
49. Quinn P.J., Boldyrev A.A., Formazuyk V.E. Carnosine: its properties, functions and potential therapeutic applications. Mol. Aspects Med. 1992, 12:379-444.
50. Rajanikant G.K., Zemke D., Senut M.C., Frenkel M.B., Chen A.F., Gupta R., et al. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. Stroke 2007, 38:3023-3031.
51. Reddy R., Fleet-Michaliszyn S., Condray R., Yao J.K., Keshavan M.S., Reddy R. Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: preliminary study. Prostaglandins Leukot. Essent. Fatty Acids 2011, 84:79-83.
52. Sassoè-Pognetto M., Cantino D., Panzanelli P., Verdun di Cantogno L., Giustetto M., Margolis F.L., et al. Presynaptic co-localization of carnosine and glutamate in olfactory neurones. NeuroReport 1993, 5:7-10.
53. Sharma, T., Harvey, P., (co-editors) 2000. Cognition in Schizophrenia. Impairments, Importance and Treatment Strategies. New York, Oxford University Press.
54. 3 receptors. Biochem. Pharmacol. 2007, 73:709-717.
55. Shen Y., He P., Fan Y.-y., Zhang J.-x., Yan H.-j., Hu W., et al. Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. Free Radic. Biol. Med. 2010, 48:727-735.
56. Smythies J. Redox mechanisms at the glutamate synapse and their significance: a review. Eur. J. Pharmacol. 1999, 370:1-7.
57. Stefani M.R., Groth K., Moghaddam B. Glutamate receptors in the rat medial prefrontal cortex regulate set shifting ability. Behav. Neurosci. 2003, 117:728-737.
58. Tamaki N., Funatsuka A., Fujimoto S., Hama T. The utilization of carnosine in rats fed on a histidine-free diet and its effect on the levels of tissue histidine and carnosine. J. Nutr. Sci. Vitaminol. 1984, 30:541-551.
59. Tamba M., Torreggiani A. Hydroxyl radical scavenging by carnosine and Cu(II) carnosine complexes: a pulse-radiolysis and spectroscopic study. Int. J. Radiat. Biol. 1999, 75:1177-1188.
60. Teuscher N.S., Keep R.F., Smith D.S. PEPT2-mediated uptake of neuropeptides in rat choroid plexus. Pharm. Res. 2001, 18:807-813.
61. Tolman A.W., Kurtz M.M. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr. Bull. 2010, 10.1093/schbul/sbq077.
62. Velligan D., Brenner R., Sicuro F., Walling D., Riesenberg R., Sfera A., et al. Assessment of the effects of AZ 3480 on cognitive function in patients with schizophrenia. Schizophre. Res. 2012, 134:59-64.
63. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med. Care 1992, 30:473-483.
64. Wood M.R.G., Johnson P. Purification of carnosine synthetase from avian muscle by affinity chromatography and determination of its subunit structure. Biochim. Biophys. Acta 1981, 662:138-144.
65. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia. CNS Drugs 2001, 15:287-310.
66. Zayat E., Rempfer M., Gajewski B., Brown C.E. Patterns of association between performance in a natural environment and measures of executive function in people with schizophrenia. Psychiatry Res. 2011, 187:1-5.
67. Ziang J., Yongjun H., Smith D., Keep R. PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006, 1122:18-23.